Sanofi announces Pluromed acquisition

Sanofi is to expand its presence in the biosurgery field through the acquisition of Pluromed, a Massachusetts-based medical technology firms.

The newly acquired business is the developer of the Rapid Transition Polymers technology line and has been credited with playing a key role in popularising the use of injectable plugs to improve the safety and efficacy of medical interventions.

Following the takeover, Sanofi will be responsible for commercialising Pluromed's LeGoo gel product for temporary endovascular occlusion of blood vessels during surgical procedures, which is approved for US and EU usage.

Alison Lawton, senior vice-president and general manager for Sanofi Biosurgery, said: "LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma."

This comes after the company earlier this week launched its new iBGStar blood glucose monitoring system, which is compatible with iPhone, iPod Touch and iPad devices.